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Abstract
Introduction It has been suggested that oxidative stress and
mitochondrial DNA damage play important roles in breast
cancer carcinogenesis. Manganese superoxide dismutase
(MnSOD) is a major enzyme that is responsible for the
detoxification of reactive oxygen species in the mitochondria. A
T → C substitution in the MnSOD gene results in a Val → Ala
change at the -9 position of the mitochondrial targeting
sequence (Val-9Ala), which alters the protein secondary
structure and thus affects transport of MnSOD into the
mitochondria.
Methods We evaluated this genetic polymorphism in
association with breast cancer risk using data from the
Shanghai Breast Cancer Study, a population-based case–
control study conducted in urban Shanghai from 1996 to 1998.
The  MnSOD  Val-9Ala polymorphism was examined in 1125
breast cancer cases and 1197 age-frequency-matched control
individual.
Results Breast cancer risk was slightly elevated in women with
Ala/Ala genotype (odds ratio [OR] 1.3, 95% confidence interval
[CI] 0.7–2.3), particularly among premenopausal women (OR
1.8, 95% CI 0.9–3.7), as compared with those with Val/Val
genotype. The increased risk with the Ala/Ala genotype was
stronger among premenopausal women with a higher body
mass index (OR 2.5, 95% CI 0.9–7.0) and more years of
menstruation (OR 2.6, 95% CI 0.8–8.0). The risk among
premenopausal women was further increased twofold to
threefold among those with a low intake of fruits, vegetables,
vitamin supplements, selenium, or antioxidant vitamins, including
carotenes and vitamins A, C, and E. However, the frequency of
the Ala allele was low (14%) in the study population, and most
of the ORs provided above were not statistically significant.
Conclusion The present study provides some evidence that
genetic polymorphism in the MnSOD gene may be associated
with increased risk of breast cancer among Chinese women
with high levels of oxidative stress or low intake of antioxidants.
Studies with a larger sample size are needed to confirm the
findings.
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Introduction
More than 90% of the body's oxygen is consumed by the
electron transport chain in mitochondria [1], and about 1–
5% of it is released as superoxide (O2
•-) and hydrogen per-
oxide (H2O2) [2]. Reactive oxygen species (ROS) may also
be generated from estrogen metabolism through catechol
estrogen redox cycling [3,4]. Because of a high level of
internally generated ROS, lack of histone protection, and a
low level of DNA repair, mitochondrial DNA is particularly
vulnerable to oxidative damage [5]. It has been suggested
that mitochondrial DNA damage may play an important role
in breast carcinogenesis [5,6]. Manganese superoxide dis-
mutase (MnSOD) and glutathione peroxidase (GPX) 1 are
two major enzymes that are responsible for ROS detoxifica-
tion in mitochondria [7,8]. The MnSOD  gene, which is
composed of five exons and four introns, is localized to
BMI = body mass index; bp = base pairs; CI = confidence interval; GPX = glutathione peroxidase; MnSOD = manganese superoxide dismutase; OR 
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chromosome 6q25 [9,10]. A T → C substitution, resulting
in a Val → Ala change at the -9 position (Val-9Ala), which
alters the secondary structure of the protein [11], has been
noted to affect transport of MnSOD into the mitochondria
[12,13]. Another polymorphism (Ile58Thr) in exon 3 affects
the stability of MnSOD and reduces protein amount and
enzyme activity [14,15]. Cells that over-expressed the Ile58
allele had higher MnSOD activity than did cells that over-
expressed the Thr58 allele [16]. It is biologically plausible
that the Val-9Ala and Ile58Thr polymorphisms play an
important role in ROS detoxification, thus affecting the risk
for developing cancer, particularly among individuals with a
higher level of oxidative stress or who are deprived of other
antioxidative protection, such as through a low level of anti-
oxidant intake.
Four studies examined the association of the Val-9Ala pol-
ymorphism with breast cancer risk, with mixed results [17-
20]. Two hospital-based case–control studies found a
moderate elevation in risk among women carrying the Ala/
Ala genotype [17,18]. A population-based case–control
study found no overall association with this polymorphism
[19]. Recently, a case–control study conducted using data
from the Ontario Familial Breast Cancer Registry found no
association with this polymorphism [20]. All four studies
were conducted among Caucasian women and had rela-
tively small sample sizes, and most of them did not include
a comprehensive assessment of environmental exposures
or lifestyle data. Using data from the Shanghai Breast Can-
cer Study, a large-scale population-based case–control
study conducted in urban Shanghai from 1996 to 1998,
we evaluated the association of the MnSOD gene polymor-
phism with breast cancer risk, in conjunction with condi-




The cases and control individuals evaluated in this study
were participants of the Shanghai Breast Cancer Study, a
population-based case–control study. Detailed study meth-
ods were published elsewhere [21]. Briefly, the study
included 1459 women aged between 25 and 64 years,
who were diagnosed with breast cancer between August
1996 and March 1998, and 1556 age-frequency-matched
control individuals. The study protocol was approved by
committees of all relevant institutions for the study of
humans in research. All study participants were permanent
residents of urban Shanghai who had no prior history of
cancer and were alive at the time of interview. Through a
rapid case ascertainment system, supplemented by the
population-based Shanghai Cancer Registry, a total of
1602 eligible patients with breast cancer were identified
during the study period, and interviews were completed in-
person by 1459 (91%) of them. The major reasons for non-
participation were refusal (109 [6.8%]), death before the
interview (17 [1.1%]), and inability to locate the person (17
[1.1%]). Cancer diagnoses for all patients were confirmed
by two senior study pathologists by review of tumor slides.
Control individuals were selected using the Shanghai Res-
ident Registry, a population registry containing demo-
graphic information for all residents of urban Shanghai, and
were frequency matched for age (5-year intervals) to the
expected age distribution of the cases in a 1:1 ratio. The
inclusion criteria for control individuals were identical to
those for the cases but with the exception of a diagnosis of
breast cancer. Of the 1724 eligible women, 1556 (90.3%)
completed interviews in-person. The remaining women
were not included in the study either because of refusal
(166 [9.6%]) or death before the interview (2 [0.1%]).
A structured questionnaire was used to elicit detailed infor-
mation on demographic factors, menstrual and reproduc-
tive histories, hormone use, dietary habits, prior disease
history, physical activity, tobacco and alcohol use, weight,
and family history of cancer. For all participants, current
weight, circumference of the waist and hips, and height
while sitting and standing were measured. Blood samples
were obtained from 1193 (82%) cases and 1310 (84%)
control individuals who completed in-person interviews.
These samples were processed on the same day, typically
within 6 hours of sample collection, and stored at -70°C
until bioassays were performed.
Usual dietary habits over the past 5 years were assessed
by in-person interview, using a validated quantitative food
frequency questionnaire [22,23]. The food frequency ques-
tionnaire included 76 food items or groups, 30 fresh vege-
tables and nine fruits, covering over 85% of foods
commonly consumed in Shanghai. During the in-person
interview, each study participant was first asked how fre-
quently she consumed a specific food or group of foods
(daily, weekly, monthly, yearly, or never), followed by a
question on how many liangs (= 50 g) of food were eaten
per unit time (day, week, month, or year) during the previous
5-year period, ignoring any recent changes in usual dietary
intake within the 5-year period. Total dietary intakes of vita-
min A (mg), carotene (mg), vitamin C (mg), vitamin E (mg),
and selenium (µg) were calculated based on data from the
Chinese Food Composition Table [24].
Genotyping method
Genomic DNA was extracted from buffy coat fractions. The
MnSOD genotypes were determined with PCR–restriction
fragment length polymorphism methods, as reported previ-
ously [17,25] but with some modification. Briefly, the prim-
ers for the Val-9Ala polymorphism were 5'-
ACCAGCAGGCAGCTGGCGCCGG-3' (forward) and 5'-
GCGTTGATGTGAGGTTCCAG-3' (reverse). The primersAvailable online http://breast-cancer-research.com/content/6/6/R647
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for the Ile58Thr  polymorphism were 5'-AGCTGGTC-
CCATTATCTAATAG-3' (forward) and 5'-TCAGTGCAG-
GCTGAAGAGAT-3' (reverse). The PCR was performed in
a PTC-200 Peltier Thermal Cycler (MJ Research Inc.,
Waltham, MA, USA). Each 20 µl of PCR mixture contained
5 ng DNA, 1× PCR buffer with 1.5 mmol/l MgCl2, 0.16
mmol/l each of dNTP, 0.5 µmol/l of each primer, and 1 unit
of HotStarTaq™ DNA polymerase (Qiagen Inc., Valencia,
CA, USA). The reaction mixture was initially denatured at
95°C for 15 min, followed by 35 cycles of 94°C for 30 s,
60°C for 30 s, and 72°C for 30 s. The PCR was completed
by a final extension cycle at 72°C for 7 min. The PCR prod-
ucts were digested by the NgoMIV and EcoRV restriction
endonucleases for the Val-9Ala and Ile58Thr polymor-
phisms, respectively. The DNA fragments were then sepa-
rated using 3% Nusieve/Agarose gel and visualized by
ethidium bromide staining.
For the Val-9Ala polymorphism, the PCR product (107 bp)
with C allele (Ala) was digested to two fragments (89 bp
and 18 bp), whereas the PCR product with T allele (Val)
cannot be cut by NgoMIV. For the Ile58Thr polymorphism
the PCR product (139 bp) with T allele (Ile) was digested
to two fragments (117 bp and 22 bp), whereas the PCR
product with C allele (Thr) cannot be cut by EcoRV. No
Ile58Thr polymorphism was found in 400 individuals in our
study, and we did not perform genotyping for this polymor-
phism in all participants.
The laboratory staff was blind to the identity of the partici-
pants. Quality control (QC) samples were included in the
genotyping assays. Each 96-well plate contained one
water, two CEPH 1347-02 DNA, two blinded QC DNA,
and two unblinded QC DNA samples. The blinded and
unblinded QC samples were taken from the second tube of
study samples included in the study. The Val-9Ala geno-
types determined for the blinded QC samples were in com-
plete agreement with the genotypes determined for the
study samples. Genotyping data were obtained from 1125
cases and 1197 control individuals. The major reasons for
incomplete genotyping were insufficient DNA and unsuc-
cessful PCR amplification.
Statistic analysis
To evaluate case–control differences for categorical data,
including genotype distribution and continuous variables,
χ2 test and t-test were used, respectively. Conditional logis-
tic regression models adjusted for age were applied to esti-
mate odds ratios (ORs) and 95% confidence intervals (CIs)
to measure the strength of the association between the
MnSOD gene Val-9Ala polymorphism and breast cancer
risk [26,27]. Analyses stratified by menopausal status and
age were conducted to check homogeneity of the associa-
tion. Additional analyses stratified by body mass index
(BMI), years of menstruation, and intake of fruits, vegeta-
bles, vitamin supplements, selenium, or antioxidant vitamins
were conducted to evaluate the potential modifying effects
of these variables on the association between the MnSOD
genotypes and breast cancer risk. A composite dietary anti-
oxidant index was derived to incorporate information on
intake of four antioxidant nutrients (i.e. selenium and vita-
mins A, C, and E) [28]. Intake of each antioxidant nutrient
was first standardized by subtracting the mean and dividing
by the standard deviation, and then the antioxidant index
was created by summing the standardized intake of these
four antioxidant nutrients with equal weight [28]. All statis-
tical tests were two-sided.
Results
The distribution of selected demographic characteristics
and major risk factors for breast cancer are shown in Table
1. Breast cancer cases and controls were similar in age
and level of education. Elevated risks were observed for all
known major breast cancer risk factors [29], including a
prior history of breast fibroadenoma, physical inactivity,
higher waist-to-hip ratio, higher BMI, early onset of
menarche, late onset of menopause, and late age at first
live birth. No apparent differences were found between
individuals with genotyping data and those included in the
whole study in any of the major known risk factors, demo-
graphic characteristics, and dietary antioxidant intake (data
not shown), indicating that the chance of selection bias in
this study is likely to be small.
The frequencies of the Ala allele were 14.3% and 14.0% in
cases and control individuals, respectively. Genotype fre-
quencies were 73.9% (Val/Val), 23.6 (Val/Ala), and 2.5%
(Ala/Ala) for cases, and the respective frequencies were
73.9%, 24.2%, and 1.9% for control individuals (Table 2).
The MnSOD Val-9Ala polymorphism was in Hardy–Wein-
berg equilibrium for both cases and control individuals. No
Ile58Thr polymorphism was found in our study population.
Thus, we report here the results for the Val-9Ala
polymorphism.
Compared with women with the Val/Val genotype, breast
cancer risk was slightly but not statistically significantly ele-
vated for women with the Ala/Ala genotype (age-adjusted
OR 1.3, 95% CI 0.7–2.3; Table 2). The Val/Ala genotype
was unrelated to risk and was combined with the Val/Val
genotype in some subsequent analyses. Additional adjust-
ment for physical activity, BMI, waist-to-hip ratio, age at
menarche, number of pregnancies, age at first birth, and
family history of breast cancer had no appreciable effect on
age-adjusted ORs, regardless of whether the analyses
were done among all participants or stratified by menopau-
sal status or age. Thus, only the age-adjusted ORs are pre-
sented. The elevated risk associated with the Ala/Ala
genotype was restricted to premenopausal women (OR
1.8, 95% CI 0.9–3.7; for postmenopausal women OR 0.8,Breast Cancer Research    Vol 6 No 6    Cai et al.
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95% CI 0.3–2.0) and women younger than 45 years (OR
1.8, 95% CI 0.7–4.3; for women older than 45 years OR
1.1, 95% CI 0.5–2.2).
Further analyses were conducted to evaluate the associa-
tion of the MnSOD Val-9Ala polymorphism and breast can-
cer risk by duration (years) of menstruation and BMI,
factors that are related to the duration and level of estrogen
exposure (Table 3). The ORs for the Ala/Ala genotype were
higher among premenopausal women with a higher BMI
(OR 2.5, 95% CI 0.9–7.0) or a longer duration of menstru-
ation (OR 2.6, 95% CI 0.8–8.0). Again, the ORs were not
statistically significant. This increased risk was not
observed in postmenopausal women (Table 3).
We further evaluated the association of the MnSOD Val-
9Ala polymorphism with breast cancer risk by dietary anti-
oxidant intake (Table 4). Intriguingly, the positive associa-
tion with the Ala/Ala genotype among premenopausal
women was consistently found to be stronger among those
who had a low intake of fruits, vegetables, selenium, or anti-
oxidant vitamins, including carotenes and vitamins A, C,
and E, than among those who had a higher intake of these
dietary factors. This pattern of association suggests a mod-
ifying effect, although neither the ORs nor the interaction
tests were statistically significant, perhaps as a result of the
small numbers of participants in the subgroups. The modi-
fying effect of these antioxidant intakes on the association
between the MnSOD Val-9Ala polymorphism and breast
cancer risk was less apparent in the analyses among post-
menopausal women. However, the postmenopausal case–
control numbers were small. To illustrate the joint effects of
dietary antioxidant intake, we further evaluated the associa-
tion of the MnSOD Val-9Ala polymorphism with breast can-
cer risk by dietary antioxidant index. ORs for the Ala/Ala
genotype were 2.4 (95% CI 0.6–9.5) and 2.2 (95% CI
0.5–9.4) among premenopausal and postmenopausal
women, respectively, who had a lower dietary antioxidant
index.
Discussion
Ambrosone and colleagues previously reported that Val/Val
genotype was significantly associated with an increased
risk of breast cancer among premenopausal Caucasian
women, particularly those who had a low intake of fruits and
vegetables and of dietary ascorbic acid and α-tocopherol
[17]. In this large-scale, population-based, case–control
study, we found that breast cancer risk was slightly but not
significantly elevated in Chinese women with the Ala/Ala
genotype as compared with women with the Val/Val geno-
type, particularly among premenopausal women who had a
low intake of fruits, vegetables, selenium, or antioxidant vita-
mins. A significant association of this polymorphism with
breast cancer risk was not observed in present study,
which might partly be due to low Ala allele frequency in Chi-
nese women.
We observed in this study that women carrying the Ala/Ala
genotype who had a higher BMI or a longer duration of
menstruation were at higher risk of breast cancer, particu-
larly among premenopausal women. Some ROS may be
generated from estrogen metabolism through catechol
redox cycling [3,4]. Mitrunen and coworkers [18] con-
ducted a case–control study among 483 cases and 482
Table 1
Comparisons of cases and controls by selected demographic characteristics and major risk factors in the Shanghai Breast Cancer 
Study
Characteristic Cases (n = 1125) Controls (n = 1197) P-valuea
Demographic factors
Age (years [mean ± SD]) 47.63 ± 8.00 47.20 ± 8.78 0.217
Education, lower than middle school (%) 12.27 14.79 0.124
Major risk factors
Breast cancer in first-degree relatives (%) 3.38 2.26 0.101
Ever had breast fibroadenoma (%) 9.78 5.26 < 0.001
Age at menarche (years [mean ± SD]) 14.41 ± 1.64 14.71 ± 1.73 0.004
Age at first live birthb (years [mean ± SD]) 26.82 ± 4.07 26.17 ± 3.83 < 0.001
Age at menopausec (years [mean ± SD]) 48.17 ± 4.65 47.46 ± 4.95 0.036
Physically active in past 10 years (%) 19.40 26.00 < 0.001
Body mass index (mean ± SD) 23.54 ± 3.39 23.25 ± 3.45 0.047
Waist-to-hip ratio (mean ± SD) 0.81 ± 0.06 0.80 ± 0.06 0.004
aFrom χ2 test (categorical variables) or T test (continuous variables). bAmong parous women.
cAmong postmenopausal women. SD, standard deviation.Available online http://breast-cancer-research.com/content/6/6/R647
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controls in a Finnish Caucasian population, and reported
that the Ala allele was associated with breast cancer risk,
with an OR of 1.5 in the Ala/Ala or Val/Ala groups com-
pared with the Val/Val group. Postmenopausal women who
had used estrogen replacement therapy and carried either
the Ala/Ala or Val/Ala genotype had a 2.5-fold higher risk
for breast cancer. Women who had used oral contracep-
tives and carried the Ala/Ala or Val/Ala genotype had a 3.0-
fold higher risk for breast cancer [18]. More recently, Egan
and coworkers [19] conducted a population-based case–
control study among 476 cases and 502 controls in an
American population. Overall, relative risks were not signif-
icantly elevated in women with one (OR 1.27, 95 CI 0.91–
1.77) or two (OR 1.18, 95% CI 0.81–1.73) Ala alleles, as
compared with the Val/Val genotype. Risk, however, was
increased among premenopausal women carrying the Val/
Ala genotype (OR 1.88), but not among women carrying
the Ala/Ala genotype (OR 0.94) [19]. Women carrying the
Ala/Ala or Val/Ala genotype who had used oral contracep-
tives or had higher BMI also had an increased risk for
breast cancer [19]. Because of the low frequency of the
Ala/Ala genotype and low percentage of estrogen use
among Chinese women, we are unable to perform the anal-
yses stratified by these exogenous estrogen exposures.
Several studies have evaluated the association of the
MnSOD  Val-9Ala polymorphism with other cancers,
although the results were inconsistent among cancer sites.
Recently, Woodson and coworkers [30] reported that the
Ala/Ala genotype was associated with a 1.7-fold (95% CI
0.96–3.08) increased risk for prostate cancer as compared
with the Val/Val genotype. No association of this polymor-
phism with colorectal adenomas was found in a sigmoidos-
copy-based case–control study [31]. Recently, Lin and
coworkers [32] reported no association of the MnSOD Val-
9Ala polymorphism with lung cancer risk in a case–control
study conducted in Taiwan. Interestingly, Wang and cow-
orkers [33] reported that the Val allele was associated with
Table 2
Association between the manganese superoxide dismutase polymorphism and breast cancer risk in the Shanghai Breast Cancer 
Study
Genotype Cases (n [%]) Controls (n [%]) ORa 95% CI
All subjects
Val/Val 831 (73.9) 884 (73.9) 1.0 Reference
Val/Ala 266 (23.6) 290 (24.2) 1.0 0.8–1.2
Ala/Ala 28 (2.5) 23 (1.9) 1.3 0.7–2.3
Val/Val and Val/Ala 1097 (97.5) 1174 (98.1) 1.0 Reference
Ala/Ala 28 (2.5) 23 (1.9) 1.3 0.7–2.3
Stratified analyses by menopausal status
Premenopausal women
Val/Val and Val/Ala 729 (97.2) 751 (98.4) 1.0 Reference
Ala/Ala 21 (2.8) 12 (1.6) 1.8 0.9–3.7
Postmenopausal women
Val/Val and Val/Ala 363 (98.1) 419 (97.4) 1.0 Reference
Ala/Ala 7 (1.9) 11 (2.6) 0.8 0.3–2.0
P for interaction = 0.147
Stratified analyses by age
Age < 45 years
Val/Val and Val/Ala 442 (97.1) 488 (98.4) 1.0 Reference
Ala/Ala 13 (2.9) 8 (1.6) 1.8 0.7–4.3
Age ≥ 45 years
Val/Val and Val/Ala 655 (97.8) 686 (97.9) 1.0 Reference
Ala/Ala 15 (2.2) 15 (2.1) 1.1 0.5–2.2
P for interaction = 0.380
aAdjusted for age. CI, confidence interval; OR, odds ratio.Breast Cancer Research    Vol 6 No 6    Cai et al.
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lung cancer risk with ORs of 1.34 (95% CI 1.05–1.70) and
1.67 (95% CI 1.27–2.20) in the Val/Ala and Val/Val group,
respectively. These differences in the associations of the
MnSOD genotype with breast and lung cancers suggest
that the role played by MnSOD in carcinogenesis may vary
for different tumors. The mechanism underlying this tumor
type difference remains to be investigated.
The SODs are the first and most important line of antioxi-
dant enzyme defense against ROS and particularly O2
•-
radical. It was predicted that MnSOD Val-9Ala polymor-
phism might alter transfer of the MnSOD enzyme into mito-
chondria [11,12]. Recently, Sutton and coworkers [13]
reported that the Ala-MnSOD precursor generated 30–
40% more of the active, matricial, and processed MnSOD
homotetramer in mitochondrial matrix than did Val-MnSOD.
Some human tumor cells lost MnSOD activity, and this loss
has been shown to be responsible for at least part of the
malignant phenotype [34,35]. MnSOD knockout mice
exhibited increased oxidative DNA damage [36]. Over-
expression of MnSOD in MCF-7 cell suppressed the malig-
nant phenotype, as evidenced by decreased cell prolifera-
tion, clonogenic fraction in soft agar culture, and tumor
growth in nude mice [37]. Recently, Soini and coworkers
[38] reported that MnSOD expression is less frequent in
the tumor cells of invasive breast carcinomas than in in situ
carcinomas or non-neoplastic breast epithelial cells.
Three distinct isoforms of SOD have been identified in
mammals. These three isoforms are encoded by three dis-
tinct genes located on different chromosomes [10]. All
three SOD genes are polymorphic. It would be interesting
to analyze jointly all of the three genes to evaluate any
gene–gene interaction in relation to breast cancer risk. O2
•-
, if not scavenged by SOD, may react with nitric oxide rad-
ical (NO•) to form the strong oxidant peroxynitrite (ONOO-
) [39]. MnSOD dismutates O2
•- to H2O2, which is further
detoxified by GPX1 in mitochondria. If not be quenched,
H2O2 will be converted to the more toxic hydroxyl radical
(•OH). Thus, study of the joint effect of the MnSOD, nitric
oxide synthase, and GPX1 gene polymorphisms might pro-
vide further information on the role played by oxidative
stress in cancer risk.
Frequencies of the Val and Ala alleles of the MnSOD Val-
9Ala polymorphism in our control population were 86.0%
and 14.0%, respectively. The minor allele (Ala) frequency
(14.0%) is comparable with that in Japanese (14.1%) [40]
and Chinese (11.5%) [41] populations, but substantially
lower than that in Caucasian populations [17-20]. The low
frequency of the Ala allele in our study population contrib-
Table 3
Associations of breast cancer with the manganese superoxide dismutase polymorphism, stratified by lifestyle factors, in the 
Shanghai Breast Cancer Study
Stratified variable (by median) MnSOD genotypes
Val/Val Val/Ala Ala/Ala
na ORb (95% CI) na ORb (95% CI) na ORb (95% CI)
Premenopausal women
BMI
≤ Median 250/275 1.0 (ref.) 73/99 0.9 (0.6–1.2) 8/7 1.3 (0.5–3.7)
> Median 300/288 1.0 (ref.) 106/89 1.1 (0.8–1.6) 13/5 2.5 (0.9–7.0)
Years of menstruationc
≤ Median 203/286 1.0 (ref.) 77/91 1.2 (0.8–1.7) 8/8 1.4 (0.5–3.7)
> Median 347/277 1.0 (ref.) 102/97 0.8 (0.6–1.2) 13/4 2.6 (0.8–8.0)
Postmenopausal women
BMI
≤ Median 126/156 1.0 (ref.) 39/52 1.0 (0.6–1.6) 4/7 0.7 (0.2–2.5)
> Median 152/161 1.0 (ref.) 46/50 1.0 (0.6–1.6) 3/4 0.8 (0.2–3.7)
Years of menstruationc
≤ Median 128/172 1.0 (ref.) 44/54 1.1 (0.7–1.8) 2/6 0.4 (0.1–2.2)
> Median 150/145 1.0 (ref.) 41/48 0.8 (0.5–1.3) 5/5 1.0 (0.3–3.5)
aNumber of cases/controls. bAdjusted for age. cYears of menstruation = menopausal age or age at interview for premenopausal women – 
menarche age. CI, confidence interval; MnSOD, manganese superoxide dismutase; OR, odds ratio; ref., reference.Available online http://breast-cancer-research.com/content/6/6/R647
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utes to a wider range of 95% CIs in OR estimations and limits the
statistical power for stratified analyses. Small numbers of individ-
uals, such as in the subgroups stratified by menopausal status in
the present study, may result in unstable OR estimates. Studies
with a larger sample size are needed to confirm the findings.
The current study has many strengths. First, the high participation
rate and the population-based study design substantially reduce
selection bias. Second, Chinese women living in Shanghai are rel-
atively homogenous in their ethnic background; over 98% are
from a single ethnic group (Han Chinese). Therefore, the potential
confounding effect of ethnicity is not a major concern in this study.
Third, the extensive information collected on lifestyle factors
allowed comprehensive evaluation of their interaction with genetic
polymorphisms. The risk estimates derived from age-adjusted and
Table 4
Associations of breast cancer with the manganese superoxide dismutase polymorphism polymorphism, stratified by food and nutrient intake, in 
the Shanghai Breast Cancer Study
Stratified variable Premenopausal women Postmenopausal women
Val/Val Val/Ala Ala/Ala Val/Val Val/Ala Ala/Ala













≤ Median 273/290 1.0 (ref.) 89/88 1.1 (0.8–1.6) 9/4 2.4 (0.7–8.0) 145/164 1.0 (ref.) 49/44 1.3 (0.8–2.0) 4/6 0.7 (0.2–2.7)
> Median 277/273 1.0 (ref.) 90/100 0.9 (0.6–1.2) 12/8 1.5 (0.6–3.7) 133/153 1.0 (ref.) 36/58 0.7 (0.5–1.2) 3/5 0.8 (0.2–3.3)
Total fruits
≤ Median 260/281 1.0 (ref.) 95/98 1.1 (0.8–1.5) 7/3 2.6 (0.7–10.0) 152/166 1.0 (ref.) 38/44 1.0 (0.6–1.6) 4/5 1.0 (0.3–3.8)
> Median 290/282 1.0 (ref.) 84/90 0.9 (0.6–1.2) 14/9 1.5 (0.7–3.6) 126/151 1.0 (ref.) 47/58 1.0 (0.6–1.5) 3/6 0.6 (0.1–2.3)
Vitamin A
≤ Median 238/286 1.0 (ref.) 86/92 1.1 (0.8–1.6) 10/4 2.9 (0.9–9.2) 111/165 1.0 (ref.) 29/46 1.0 (0.6–1.6) 5/4 1.9 (0.5–7.3)
> Median 312/277 1.0 (ref.) 93/96 0.9 (0.6–1.2) 11/8 1.3 (0.5–3.3) 167/152 1.0 (ref.) 55/56 0.9 (0.6–1.4) 2/7 0.3 (0.1–1.3)
Carotene
≤ Median 281/287 1.0 (ref.) 88/90 1.0 (0.7–1.5) 10/4 2.6 (0.8–8.4) 131/157 1.0 (ref.) 41/52 0.9 (0.6–1.5) 3/6 0.6 (0.1–2.4)
> Median 269/276 1.0 (ref.) 91/98 0.9 (0.7–1.3) 11/8 1.4 (0.5–3.5) 147/160 1.0 (ref.) 44/50 1.0 (0.6–1.6) 4/5 0.9 (0.2–3.4)
Vitamin E
≤ Median 288/282 1.0 (ref.) 96/95 1.0 (0.7–1.4) 10/5 1.9 (0.7–5.7) 156/155 1.0 (ref.) 48/53 0.9 (0.6–1.5) 4/7 0.6 (0.2–2.1)
> Median 262/281 1.0 (ref.) 83/93 1.0 (0.7–1.4) 11/7 1.8 (0.7–4.9) 122/162 1.0 (ref.) 37/49 1.1 (0.6–1.7) 3/4 1.0 (0.2–4.8)
Vitamin C
≤ Median 275/282 1.0 (ref.) 92/96 1.0 (0.7–1.4) 12/4 3.1 (1.0–9.8) 137/161 1.0 (ref.) 43/48 1.1 (0.7–1.7) 5/6 1.0 (0.3–3.3)
> Median 275/281 1.0 (ref.) 87/92 1.0 (0.7–1.3) 9/8 1.1 (0.4–3.0) 141/156 1.0 (ref.) 42/54 0.9 (0.6–1.4) 2/5 0.5 (0.1–2.5)
Selenium
≤ Median 256/278 1.0 (ref.) 78/101 0.9 (0.6–1.2) 6/3 2.1 (0.5–8.6) 115/164 1.0 (ref.) 37/48 1.1 (0.7–1.8) 5/3 2.3 (0.5–9.9)
> Median 294/285 1.0 (ref.) 101/87 1.1 (0.8–1.6) 15/9 1.7 (0.7–3.9) 163/153 1.0 (ref.) 48/54 0.9 (0.5–1.3) 2/8 0.3 (0.1–1.2)
Vitamin supplement
No 488/480 1.0 (ref.) 162/174 0.9 (0.7–1.2) 20/10 1.9 (0.9–4.2) 227/255 1.0 (ref.) 70/80 1.0 (0.7–1.5) 5/10 0.6 (0.2–1.7)
Yes 62/83 1.0 (ref.) 17/14 1.6 (0.7–3.6) 1/2 0.7 (0.1–7.8) 51/62 1.0 (ref.) 15/22 0.9 (0.4–2.0) 2/1 2.1 (0.2–24.3)
Dietary antioxidant 
indexc
≤ Median 262/280 1.0 (ref.) 89/98 1.0 (0.7–1.4) 7/3 2.4 (0.6–9.5) 126/161 1.0 (ref.) 43/51 1.1 (0.7–1.8) 5/3 2.2 (0.5–9.4)
> Median 288/283 1.0 (ref.) 90/90 1.0 (0.7–1.4) 14/9 1.6 (0.7–3.8) 152/156 1.0 (ref.) 42/51 0.9 (0.5–1.4) 2/8 0.3 (0.1–1.2)
aNumber of cases/controls. bAdjusted for age. cDietary antioxidant index was derived as described in the Methods section. CI, confidence interval; OR, odds 
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multivariable adjusted analyses were similar, indicating that
a confounding effect is unlikely to be a concern in this
study.
Conclusion
In this population-based case–control study conducted in
Chinese women, we found that the MnSOD Ala/Ala geno-
type was associated with a slightly but nonsignificantly ele-
vated risk of breast cancer. The positive association was
more evident among premenopausal women, particularly
among those who consumed a low level of antioxidant vita-
mins or with high levels of oxidative stress. However, the
study is limited by the low frequency of the Ala allele in the
Chinese population, and most of the ORs were not statisti-
cally significant. Studies with a larger sample size are
needed to confirm the findings.
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